Using magnetic resonance spectroscopy to identify biomarkers in Type 3 Gaucher disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize neurometabolite profiles in adult patients with Type 3 Gaucher disease (GD3) using magnetic resonance spectroscopy (MRS). The research focuses on identifying novel biomarkers that can indicate treatment response and evaluating the relationships between these neurometabolites and various disease parameters, including genotype and enzyme levels. By understanding these profiles, the study seeks to enhance the understanding of neurological involvement in GD3 patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All participants must be 18 years or older.
* All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.
* Individuals with GD3 who are medically stable for participation in study in the opinion of the investigator.

Exclusion Criteria:

* Medically unstable conditions as determined by the investigators.
* Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.
* Women who are pregnant or lactating or of child-bearing age that are not using acceptable forms of contraception.
* Patients enrolled in another interventional study.
* Patients who cannot or are unwilling to have blood drawn.
* Inability to undergo Magnetic Resonance Imaging (MRI) scanning, including but not limited to unable to remain still in an MRI scanner for more than 30 minutes, claustrophobia, presence of paramagnetic substances or pacemakers in body, weight over 300 lbs.
* Unable to adhere to study protocol for whatever reason.

Where it's running

• University of Minnesota
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Reena Kartha, PhD
• Email: rvkartha@umn.edu
• Phone: 612-626-2436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In utero enzyme replacement therapy for lysosomal storage disorders

  This study is testing whether giving enzyme replacement therapy to unborn babies with lysosomal storage disorders can improve their health and development before they are born.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04532047

• Gaucher Disease: Following Patients on Standard Care to See How It Progresses

  This study will observe people with Gaucher disease who are receiving standard care to see how their condition changes over time and to explore the biology behind persistent or worsening disease.

  Recruiting Yale University · New Haven, Connecticut · NCT07758816

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Prevalence of Acid Sphingomyelinase Deficiency and Gaucher Disease in Patients with Monoclonal Gammopathies

  This study is trying to see how common Acid Sphingomyelinase Deficiency and Gaucher Disease are in patients with monoclonal gammopathies, especially those with an enlarged spleen or who have had their spleen removed.

  Recruiting at 23 sites Fundación Española de Hematología y Hemoterapía · Vitoria-Gasteiz, Alava and 22 other locations · NCT05992532

• Exploring extracellular vesicles in Gaucher Disease

  This study is trying to see how certain tiny particles in the body behave differently in people with Gaucher Disease compared to healthy individuals to understand their role in communication between cells and possible links to brain inflammation.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT05843552

• Ambroxol for people with Gaucher disease or GBA-related Parkinson's disease

  This project tests whether ambroxol is safe and may help people with Gaucher disease or Parkinson's disease caused by GBA gene changes.

  Recruiting at 3 sites Shaare Zedek Medical Center · Jerusalem, Please Select... and 2 other locations · NCT04388969

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.